Impact of BMPR2 Mutation on the Severity of Pulmonary Arterial Hypertension: a Systematic Review and Meta-analysis

Overview

Journal Respir Res

Specialty Pulmonary Medicine

Date 2025 Feb 28

PMID 40022182

Authors

Jixing Wu

Qian Huang

Yating Zhang

Zhesong De

Hao Fu

Yuan Zhan

Yiya Gu

Jungang Xie

Affiliations

Soon will be listed here.

Abstract

Objective: To evaluate the association between PAH severity in patients with and without BMPR2 mutation. Additionally, subgroup analyses were also performed to investigate whether differences existed among different ethnicities.

Methods: A literature search of the PubMed-MEDLINE, EMBASE, Web of Science, Scopus, and Cochrane Central Register of Controlled Trials databases was conducted from inception through June, 2024, to identify eligible studies. Analyses were performed using Stata.

Results: Seventeen nonrandomized studies comprising a total of 2,190 patients were included in the analysis. Among the hemodynamic variables, the mPAP (WMD = 6.41, 95% CI: 5.07 ~ 7.76, P = 0.000), PVR (WMD = 3.66, 95% CI: 2.79 ~ 4.53, P = 0.000), CI (WMD=-0.38, 95% CI: -0.45 ~ -0.32, P = 0.000), and CO (WMD=-0.60, 95% CI: -0.99 ~ -0.21, P = 0.003) were significantly different at diagnosis between patients with and without BMPR2 mutations. No significant differences were found in RAP and PAWP. Furthermore, subgroup analysis was conducted on data showing significant differences, revealing no significant differences in mPAP and PVR between Asian and Caucasian patients with BMPR2 mutations. However, significant differences in CI and CO were observed between these two ethnic groups, with CI and CO in Caucasians being more affected by BMPR2 mutations and decreasing more than in Asians.

Conclusion: There is a statistically significant difference in the hemodynamic variables of PAH between BMPR2 mutation carriers and non-carriers, highlighting the mutation's impact on PAH severity. This influence is not associated with ethnicity in mPAP and PVR; however, it is associated with ethnicity in CI and CO, with Caucasians being more affected by BMPR2 mutations than Asians. This suggests that Caucasians may be more sensitive to BMPR2 mutations. These findings underscore the necessity of genetic testing for PAH patients, particularly among the Caucasian population. Given the poorer clinical phenotype and prognosis of BMPR2 mutation carriers, closer follow-up may be required.

References

Liang K, Chang S, Chen Y, Lin W, Tsai W, Wang K . Whole Exome Sequencing of Patients With Heritable and Idiopathic Pulmonary Arterial Hypertension in Central Taiwan. Front Cardiovasc Med. 2022; 9:911649. PMC: 9256950. DOI: 10.3389/fcvm.2022.911649. View

Zhang R, Wang X, Zhang H, Sun X, Zhao Q, Wang L . Profiling nitric oxide metabolites in patients with idiopathic pulmonary arterial hypertension. Eur Respir J. 2016; 48(5):1386-1395. DOI: 10.1183/13993003.00245-2016. View

Rich S . The current treatment of pulmonary arterial hypertension: time to redefine success. Chest. 2006; 130(4):1198-202. DOI: 10.1378/chest.130.4.1198. View

Theobald V, Grunig E, Benjamin N, Seyfarth H, Halank M, Schneider M . Is iron deficiency caused by mutations or dysfunction in pulmonary arterial hypertension patients?. Pulm Circ. 2023; 13(2):e12242. PMC: 10247310. DOI: 10.1002/pul2.12242. View

Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M . Prognostic Value of Follow-Up Hemodynamic Variables After Initial Management in Pulmonary Arterial Hypertension. Circulation. 2017; 137(7):693-704. DOI: 10.1161/CIRCULATIONAHA.117.029254. View

Zhang R, Wang L, Zhao Q, Jiang R, Gong S, Jiang X . Alteration of Extracellular Superoxide Dismutase in Idiopathic Pulmonary Arterial Hypertension. Front Med (Lausanne). 2020; 7:509. PMC: 7705200. DOI: 10.3389/fmed.2020.00509. View

Humbert M, Kovacs G, Hoeper M, Badagliacca R, Berger R, Brida M . 2022 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur Respir J. 2022; 61(1). DOI: 10.1183/13993003.00879-2022. View

Soon E, Crosby A, Southwood M, Yang P, Tajsic T, Toshner M . Bone morphogenetic protein receptor type II deficiency and increased inflammatory cytokine production. A gateway to pulmonary arterial hypertension. Am J Respir Crit Care Med. 2015; 192(7):859-72. PMC: 4613895. DOI: 10.1164/rccm.201408-1509OC. View

Isobe S, Kataoka M, Aimi Y, Gamou S, Satoh T, Fukuda K . Improved Survival of Patients with Pulmonary Arterial Hypertension with BMPR2 Mutations in the Last Decade. Am J Respir Crit Care Med. 2016; 193(11):1310-4. DOI: 10.1164/rccm.201601-0158LE. View

10.

Cogan J, Pauciulo M, Batchman A, Prince M, Robbins I, Hedges L . High frequency of BMPR2 exonic deletions/duplications in familial pulmonary arterial hypertension. Am J Respir Crit Care Med. 2006; 174(5):590-8. PMC: 2648061. DOI: 10.1164/rccm.200602-165OC. View

11.

Benza R, Gomberg-Maitland M, Elliott C, Farber H, Foreman A, Frost A . Predicting Survival in Patients With Pulmonary Arterial Hypertension: The REVEAL Risk Score Calculator 2.0 and Comparison With ESC/ERS-Based Risk Assessment Strategies. Chest. 2019; 156(2):323-337. DOI: 10.1016/j.chest.2019.02.004. View

12.

Chang K, Duval S, Badesch D, Bull T, Chakinala M, De Marco T . Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry. J Am Heart Assoc. 2022; 11(9):e024969. PMC: 9238604. DOI: 10.1161/JAHA.121.024969. View

13.

Girerd B, Montani D, Eyries M, Yaici A, Sztrymf B, Coulet F . Absence of influence of gender and BMPR2 mutation type on clinical phenotypes of pulmonary arterial hypertension. Respir Res. 2010; 11:73. PMC: 2898773. DOI: 10.1186/1465-9921-11-73. View

14.

Tio D, Leter E, Boerrigter B, Boonstra A, Vonk-Noordegraaf A, Bogaard H . Risk factors for hemoptysis in idiopathic and hereditary pulmonary arterial hypertension. PLoS One. 2013; 8(10):e78132. PMC: 3806771. DOI: 10.1371/journal.pone.0078132. View

15.

Liu D, Wu W, Mao Y, Yuan P, Zhang R, Ju F . BMPR2 mutations influence phenotype more obviously in male patients with pulmonary arterial hypertension. Circ Cardiovasc Genet. 2012; 5(5):511-8. DOI: 10.1161/CIRCGENETICS.111.962209. View

16.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

17.

Morrell N, Aldred M, Chung W, Elliott C, Nichols W, Soubrier F . Genetics and genomics of pulmonary arterial hypertension. Eur Respir J. 2018; 53(1). PMC: 6351337. DOI: 10.1183/13993003.01899-2018. View

18.

Cuthbertson I, Morrell N, Caruso P . Mutation and Metabolic Reprogramming in Pulmonary Arterial Hypertension. Circ Res. 2023; 132(1):109-126. DOI: 10.1161/CIRCRESAHA.122.321554. View

19.

Chemla D, Castelain V, Herve P, Lecarpentier Y, Brimioulle S . Haemodynamic evaluation of pulmonary hypertension. Eur Respir J. 2002; 20(5):1314-31. DOI: 10.1183/09031936.02.00068002. View

20.

Prins K, Thenappan T . World Health Organization Group I Pulmonary Hypertension: Epidemiology and Pathophysiology. Cardiol Clin. 2016; 34(3):363-74. PMC: 4959804. DOI: 10.1016/j.ccl.2016.04.001. View